Anti-Cytokeratin CAM5.2 Reagent (Becton Dickinson Biosciences) Can Detect CK 8, Not CK8/18—Comment on “Sonographic Findings in a Patient with Neurofibromatosis Type 1 and a Gastrointestinal Stromal Tumor,” J Clin Ultrasound 2010 Jan 20 [Epub ahead of print]
✍ Scribed by Pin-Jie Chen; Jeng-Dong Hsu; Chih-Ping Han
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 47 KB
- Volume
- 38
- Category
- Article
- ISSN
- 0091-2751
No coin nor oath required. For personal study only.
✦ Synopsis
W e read with great interest the article enti- tled ''Sonographic Findings in a Patient with Neurofibromatosis Type 1 and a Gastrointestinal Stromal Tumor'' by Girtler and colleagues. 1 However, one aspect of this article requires clarification, as the authors may have inadvertently interpreted CAM5.2 as cytokeratins 8/18 (within parentheses), which suggests that CAM5.2 is identical to CK8/18.
Becton Dickinson Biosciences (San Jose, CA) has developed, manufactured, and marketed the anti-cytokeratin CAM5.2 reagent (clone CAM5.2), which has often been mistaken for CK 8 and 18 monoclonal antibodies, since the previous results by Makin et al are attributed to breakdown products of cytokeratin 8, giving smaller molecular weight fractions on immunoblots. 2 In 1997, Becton Dickinson Biosciences revised the data sheet for anti-cytokeratin CAM 5.2 (Catalog No. 349205) and listed the primary reactivity as being to cytokeratin 8 and to a lesser extent to cytokeratin 7, not cytokeratin 18 or 19. 3 On the other hand, CK8/18 mouse monoclonal antibody, which is derived from the clone 5D3 that reacts against cytokeratins 8 and 18, is manufactured by Imgenex, Leica Microsystems Ltd. and is available worldwide. [4][5][6]